Dapirolizumab pegol - Biogen/UCB
Alternative Names: Anti-CD40L Fab; Anti-CD40L Fab-PEG; BIIB 133; CD40L - Fab; CDP-7657; DZP; Peg-dapirolizumab; Pegylated anti-CD40L antibodyLatest Information Update: 01 Oct 2024
At a glance
- Originator Biogen Idec; UCB
- Developer ALS Therapy Development Institute; Biogen; UCB
- Class Anti-inflammatories; Antibodies; Antirheumatics; Fab fragments; Polyethylene glycols
- Mechanism of Action CD40 ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Systemic lupus erythematosus
- Discontinued Amyotrophic lateral sclerosis; Multiple sclerosis; Rheumatoid arthritis
Most Recent Events
- 24 Sep 2024 Efficacy and adverse events data from phase-III PHOENYCS GO trial in Systemic lupus erythematosus released by UCB
- 30 Jul 2024 Discontinued - Phase-II for Multiple sclerosis (Treatment-experienced) in France (IV) prior to July 2024
- 28 Jun 2024 Discontinued - Preclinical for Amyotrophic lateral sclerosis in USA (Parenteral)